BCL2 and B-cell chronic lymphocytic leukemia: Surprisingly, the activity of venetoclax in such BH3 profiling assays could not be readily distinguished from BH3 mimetics targeting other pro-survival BCL2 proteins despite these inhibitors being substantially less active in intact CLL cells.